Morphological evaluation of apoptosis induced by salicylates in HT-1080 human fibrosarcoma cells  by Mahdi, Eamon J. et al.
Journal of Microscopy and Ultrastructure 2 (2014) 20–27
Contents lists available at ScienceDirect
Journal  of  Microscopy  and  Ultrastructure
jou rn al hom ep age : www.elsev ier .com/ locate / jmau
Original  Article
Morphological  evaluation  of  apoptosis  induced  by  salicylates
in  HT-1080  human  ﬁbrosarcoma  cells
Eamon  J. Mahdia, Abdulrahman  M.  Alshahranib,
Asma  A.  Abdulsatara,  Jassem  G.  Mahdib,∗
a Cardiff School of Medicine, Cochrane Medical Education Centre, Heath Park, Cardiff, UK
b College of Medicine, Shaqra University, Shaqra, Saudi Arabia
a  r  t  i c  l  e  i  n  f  o
Article history:
Received 16 December 2013
Received in revised form 7 February 2014
Accepted 18 February 2014
Available online 7 March 2014
a  b  s  t  r  a  c  t
Salicylates  are  a group  of  phenolic  compounds  that  are found  naturally  in plants.  They
exert  anti-inﬂammatory  and  pro-apoptosis  activities.  Three  salicylates  (acetyl  salicylic  acid,
ASA; acetyl  salicylate  calcium,  ASCa  and  salicylate  calcium,  SACa)  were  tested  in  human
ﬁbrosarcoma  cells  for  their  apoptotic  activities  in HT-1080  cells  using  both  biochemical
and  morphological  approaches.  Salicylates-treated  HT-1080  cells  exhibited  typical  apop-
totic features,  including  membrane  blebbing,  shrinkage  of the  cell  and  fragmentation  intoKeywords:
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apoptotic  bodies.  The  effects  of  the DNA  labelling  agent,  BrdU,  resulted  in more  rounder
smaller  and  a  smooth  membrane  in HT-1080  cells. These  salicylate  compounds  demon-
strated  anti-proliferation  and  reduced  the  metabolic  activities  of  HT-1080  cells  by  time-
and concentration-dependent  manners.
© 2014  Saudi  Society  of  Microscopes.  Published  by Elsevier  Ltd.  All  rights  reserved.1. Introduction
Acetylsalicylic acid (ASA), or aspirin, and its precursor
salicylic acid (SA) are common drugs which are associated
with the -d-salicin compound and are found abundantly
in the medicinal willow tree [1]. The medicinal virtue
of  the willow has been well known since the Assyrians
and Sumerians more than 6000 years ago [1]. Chemi-
cally, ASA and SA are classiﬁed as simple phenolic acids.
These acids encompass different analogues that have a
hydroxyl  group at different positions on benzene ring moi-
ety.  Salicylates belong to non-steroidal anti-inﬂammatory
drugs (NSAIDs) and exhibit multiple therapeutic activ-
ities  such as anti-pyretic and anti-inﬂammatory action
via  the inhibition of COX-2 and its expression via
∗ Corresponding author. Tel.: +966 557533678.
E-mail address: jmahdi@su.edu.sa (J.G. Mahdi).
http://dx.doi.org/10.1016/j.jmau.2014.02.005
2213-879X/© 2014 Saudi Society of Microscopes. Published by Elsevier Ltd. All riNF-B [2]. The activation of this transcription factor pro-
vides  the potential link between inﬂammation and cancer.
NF-B  formation is the consequence of an inﬂammatory
microenvironment during malignant development. It up-
regulates  the expression of cancer-promoting cytokines,
including IL-6 or TNF-, and survival genes, such as Bcl-
XL [3]. Epidemiological-related studies have indicated that
salicylates play a signiﬁcant role as protective agents
against types of breast, colorectal, gastric and oral can-
cers  [4–7]. In addition, researchers in vitro indicated that
hydroxybenzoate metal ion (Na+, Li+, Ca2+ and Zn2+)
complexes modulated the microenvironment of various
cancer cell lines by inducing apoptosis [8–10]. The asso-
ciation of apoptosis is a mechanism contributory to
how  salicylates may  prevent or act as anticancer agent
[11–14].
Apoptosis is tightly regulated physiological mechanism
that involves modulation of molecular biology, including
caspases and kinases [15]. The regulation of apoptosis
ghts reserved.
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Fig. 1. Chemical struc
s critical to the pathogenesis of a number of diseases,
ncluding cancer [16]. Under normal conditions, both cell
roliferation and apoptosis are balanced. However, if this
alance  is shifted in favour of an enhanced survival of dam-
ged  cells promote the carcinogenic process by allowing
he  survival of potentially neoplastic cells [17]. The sig-
iﬁcance of apoptosis has attracted research to explore
he  molecular signalling pathway mechanisms, includ-
ng  the initiation, mediation, execution and regulation of
poptosis.  Intensive efforts have identiﬁed two major path-
ays  for apoptosis. These are the extrinsic pathway (death
eceptor  pathway) or the intrinsic pathway (the mitochon-
rial  pathway) [18].
Morphologically, apoptosis was ﬁrst characterised by
hanges in chromatin condensation, cellular shrinkage,
udding and apoptotic body formation [19,20]. Scanning
lectron microscope is an important technique for detec-
ing  subcellular changes in apoptotic cells. These changes
eﬂect cellular biochemical changes induced by extrinsic
r  intrinsic factors [18]. The morphological expression of
rug-treated cell is a useful approach which enables an
nderstanding of the changes caused by drugs. The aim of
his  research was to study the pro-apoptotic activities of
 salicylates (Fig. 1) morphologically in HT-1080 ﬁbrosar-
oma cells and in the presence of 5-bromo,2-deoxy uridine
BrdU).
.  Materials and methods
ASA  was obtained from Sigma, UK. ASCa and SACa
ompounds were prepared by acid base reaction of the
orresponding starting materials ASA and SA (Sigma, UK),
espectively. ASCa and SACa compounds were puriﬁed
y  crystallisation from water ethanol 40:60 mixture. 5-
romo,2-deoxy uridine (BrdU) was obtained from Sigma,
K.  Stock solutions of chemical compounds were prepared
t  different concentrations in Dulbecco’s Modiﬁed Eagle’s
edium (DMEM).
The  human ﬁbrosarcoma cell line HT-1080 was  cultured
t  different cell densities in DMEM medium contained 10%
oetal  calf-serum (FCS, Gibco, U.K), l-glutamine (Gibco, UK),
%  gantamicin solution (Gibco, UK), 1% l-glutamine (Gibco,
K),  0.1% hepes buffer (Gibco, UK), 0.1% sodium pyruvate
Gibco, UK), 0.1% ascorbic acid powder (Sigma–Aldrich, UK)
nd  1 ml/100 ml  gentamycin solution. Cells were incubated
t  37 ◦C in a humidiﬁed atmosphere and 5% CO2. First the
rowth curve was performed to identify the exponential
hase for drug treatment.SACa
 ASA, ASCa and SACa.
2.1.  Cell viability assay
HT-1080  cells were seeded into 96-well plates at a
density of 15 × 103 cells in 100 l of media per well.
Cells were left for 24 h to attach to the surface. Media
was replaced with 100 l containing different concentra-
tions of salicylate compounds (0, 0.4, 0.8, 2, 4, 6, and
8  mM).  Cells were allowed to grow in the presence of
individual salicylate compound for 24, 48 and 72 h. In
addition, BrdU (0, 200, 400, 600, and 1000 M)  was sep-
arately seeded in HT-1080 cell culture and cells were
allowed to grow for 48 h. At the end of cell incubation, the
media  were replaced with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT, Sigma–Aldrich,
UK) reagent in free FCS DMEM and incubated for 60 min  at
37 ◦C. Cells were then further incubated at the same con-
ditions with MTTlysis buffer for 80 min  before reading the
absorption of formazane at 575 nm.
2.2. Cell proliferation assay
HT-1080  cells were seeded, cultured and allowed to
settle  as in the cell viability assay. Cultured cells were
incubated with different concentrations of salicylates (0,
4  and 6 mM),  containing 200 M BrdU-labelling reagent
and allowed cell to grow for 48 h. Cells were then ﬁxed
with FixDenat solution and incubated with anti-BrdU-
horseradish peroxidise (HRP)-Fab antibody-fragments to
bind  the BrdU in the newly synthesised cellular DNA.
The  immune complexes were detected by using 3,3′,5,5′-
tetramethylbenzidine (TMB) substrate and quantiﬁed by
measuring  the absorbance at 370 nm.
2.3.  Cell cycle analysis
HT-1080  cells were seeded in T-25 ﬂasks (Coster) at
an  initial density of 1 × 103 cells per ﬂask. Cells were cul-
tured as described in previous discussions before being
treated with ASA, ASCa and SACa for 24 h. In addition, con-
trol  experiments were performed in which no salicylate
compounds were incorporated in the cultures. At the end
of  each treatment, the cells were harvested by trypsiniza-
tion, were centrifuged and re-suspended in 200 l of PBS.
Aliquots (2 ml)  of ice-cold 70% ethanol were then added
and  the cells were vortexed prior to being cooled to −20◦
for 30 min. Subsequently, 100 l of RNase (Sigma, UK)
at  a concentration of 1 mg/ml and 100 l of propidium
iodide (Biovision Incorporate, CA, USA) at a concentration
of 0.4 mg/ml  was added prior to incubation at 37 ◦C for
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Fig. 2. Time- and concentration-response curves of treated HT-1080 cells with salicylate compounds. The data was derived from MTT  cell viability
assay,  in 3 replicates, after HT-1080 cells cultured with 0–8 mM salicylate compounds for 24 h, 48 h, and 72 h under optimal culture conditions. (a)
Cell  viability after treatment with ASA, (b) cell viability after treatment with ASCa, (c) cell viability after treatment with SACa, (d) cell viability after
bsorptio
is eithertreatment  with BrdU for 48 h. The values (3 replicates) for farmazone a
the  control. Thereby cell viability for control is 100% while treatment 
(Absorptioncontrol − Absorptiontreatment/Absorptioncontrol).
30 min. The cells were analysed using a FACS Calibur ﬂow
cytometer (Becton Dickinson, UK).
2.4. Scanning electron microscopy
HT-1080 cells were seeded in a 12-well plate contain-
ing microscopic slide cover slips at density of 15 × 103 cells,
incubated for 48 h with the designated drug treatment
before ﬁxation where samples were treated for 1 h with
the  ﬁxative (0.8% glutaraldehyde, 0.6% osmium tetroxide,
2  mM CaCl2, and 0.2 M sucrose in 0.1 M sodium cacodylate
buffer pH 7.4), washed for several times in PBS buffer and
dehydrated with different concentrations of alcohol (30,
50,  70, 90, each for 5 min  and 100% for 10 min  twice). The
dehydrated samples were then dried to the critical point in
a  Blazers CPD 030 using CO2. Cell samples were mounted
onto 12 mm ‘Philips type’ aluminium stubs using silver
paint  and then gold sputter coated in an Edwards S150B
sputter coater. Finally, the samples were imaged using a
Philips  XL20 SEM under various magniﬁcations ranging
from 100× up to 2000×.
2.5.  Statistical analysisData  obtained in these experiments represent an aver-
age  of 3 replicates which were evaluated using equal
variance and paired Student’s t-test (two-tails). Along with
other  statistical analyses, Graphpad Prism 5.0 softwaren were calculated by normalising relative absorption values to that of
 below or above 100%. Normalised values were calculated as ratios of
(Graphpad Software Inc., San Diego, CA, USA) was mainly
used.
3.  Results
3.1. Cytotoxic effects of salicylates on the viability of
HT-1080 cells
The  cytotoxicity of ASA, ASCa and SACa compounds
were tested by in in vitro culture growth media using
HT-1080 human ﬁbrosarcoma cells. HT-1080 cells were
allowed to grow for 24, 48 and 72 h under optimal culture
conditions that contain different concentrations of salicy-
late  compounds. The results of MTT  assays showed that
the  metabolic activities of the three salicylates exhibited
biphasic effects; i.e. mitogenic and cytotoxic compar-
ing to the untreated HT-1080 cells. At concentrations
below approximately 2 mM and cultured for 24 and
48  h, HT-1080 cells showed an increase in the metabolic
activities (Fig. 2A–C). However, the metabolic activity of
salicylate-treated HT-1080 cells was  decreased by treat-
ment  duration (72 h) and higher concentrations (2 mM or
more)  (Fig. 2A–C).
In  addition, the effects of these three salicylate com-
pounds on the metabolic activities of HT-1080 cells
indicated that SACa caused more reduction in cell viabil-
ity  by 7–12% compared to both ASA and ASCa at 6 mM
and 8 mM (Fig. 2A–C). Similar results were obtained at
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Cells were cultured under standard growth conditions for 48 h in 3 repli-
c
w
l
t
t
t
a
e
o
t
b
c
t
t
F
s
e
effects  of salicylates on cell’s morphology. HT-1080 cellsates. BrdU (200 M)  was  incorporated in cell culture at the same time
hen individual salicylate was  added.
ower concentrations and in a similar pattern, whereas,
hese salicylates affected the viability of HT-1080 cells in
ime-  and concentration manners. However, none of the
reatments, particularly when cells were incubated for 48
nd  72 h with 4, 6 and 8 mM showed signiﬁcant differ-
nces (p = 0.05) between each pair. Fig. 2D shows the effect
f  5-bromodeoxyuriding (BrdU) on the metabolic activi-
ies  of HT-1080 cells. Fig. 2D shows a negative correlation
etween HT-1080 cells metabolic activity and BrdU con-
entrations. Therefore, 200 M of BrdU was used to assess
he  cytotoxic effects of ASA, ASCa and SACa compounds on
he  proliferation of HT-1080 cells when treated for 48 h.
ig.  3 shows that ASA, ASCa and SACa compounds did not
igniﬁcantly (p = 0.05) differ in the reduction of the prolif-
ration  of HT-1080 cells when treated for 48 h.
Fig. 4. The distribution of cell cycle phases of sa
Fig. 5. The effect of 200 M Brdu on the morphology of HT-1080 celld Ultrastructure 2 (2014) 20–27 23
3.2.  The effect of salicylates on cell cycle
Fig. 4 shows that ASA, ASCa and SACa compounds
induced similar modulation to the HT-1080 cell cycle. Incu-
bation  of HT-1080 cells with 6 mM salicylate modulated
the cell cycle in a similar pattern. Thereby the number of
cells  increased by an average of approximately 17.5% at
G0/G1  phase. In contrast, the number of cells at S-phase
decreased by an average of approximately 18.3%. These
effects are more apparent after treating HT-1080 cells for
24  h to individual salicylate and proceeded the character-
istic development of a sub G0/G1 phase associated with
the  reduction of cell metabolic activity and proliferation,
leading to apoptotic cell death.
3.3. Morphological characteristics of salicylate-treated
HT-1080 cells
The  morphological effects of the three salicylates; ASA,
ASCa  and SACa on HT-1080 cells were investigated using
mainly  scanning electron microscopy. HT-1080 was treated
with  different salicylates concentrations (0.4, 2, 6 and
8  mM)  for 48 h under standard culture conditions. As
200  M BrdU was used in determining cell proliferation, it
was  ﬁrst necessary to investigate the effect of BrdU on the
morphological properties of HT-1080. Fig. 5 compares the
effect  of 200 M BrdU on HT-1080 cells before testing thecultured with BrdU showing a clear difference in morphol-
ogy  compared to the control cells (Fig. 5B). HT-1080 cells
cultured without BrdU displayed a typical ﬂat cells with
licylate-treated HT-1080 cells for 24 h.
s (A) without BrdU and (B) with BrdU. Magniﬁcation = 500×.
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ology ofFig. 6. The combined effect of salicylates and 200 M BrdU on the morph
D)  0.4 mM SACa (magniﬁcations A–C = 500×; for D = 2000×).
the distinguishable feature of irregular shapes of neoplastic
cells  (Fig. 5A). It is interesting that the incorporation of BrdU
has  caused cells to curl up, with a round shape and appear
to  grow in small groups after 48 h of culturing (Fig. 5B). Cell
cultures  with BrdU were distinct of microvilliate and had
anchors  which assisted their pseudopodial attachments to
indicate  the viability of these cells.
Incorporation of salicylate compounds in cultured HT-
1080  cells and in the presence of 200 M BrdU also
caused cells to curl up. Fig. 6 indicates that at 0.4 mM
concentration, HT-1080 cell populations retained their
viabilities, as indicated with the appearance of anchors,
pseudopodial attachments, and rough or hairy of the cell
surface  membrane. Approximately 15% of cells treated
with 0.4 mM ASA were rounded, curled up and lost their
anchors suggesting that they underwent apoptotic cell
death  (Fig. 6A). Apoptosis is also apparent from the pres-
ence  of apoptotic bodies. Some of these cells are rounded
with a smooth cell surface but others were hairy which
may  reﬂect the stage of apoptosis. At the same con-
centration, both the ASCa (Fig. 6B) and SACa (Fig. 6C)
compounds gave different morphological features com-
pared  to untreated HT-1080 cells (Fig. 5A) and salicylic acid
treatment  (Fig. 6A).
The  main features that distinguish HT-1080 treated
with salicylate compounds are cell sizes and the charac-
teristics of their shapes. ASCa caused shrinkage of cell size
(Fig.  6B) compared to control containing of 200 M BrdU
(Fig.  5B) and both ASA and SACa (Figs. 6A and 2C). The SACa
treatment (Fig. 6C) showed the spongiest appearance in the
cell  membrane which can be attributed to the changes in
cell  cytology leading to death by apoptosis. At higher mag-
niﬁcation, some of the HT-1080 cells showed clear blebbing HT-1080 cells cultured for 48 h (A) 0.4 mM ASA, (B) 0.4 mM ASCa, (C and
on  the cell surface which is a key feature of cells undergoing
apoptosis (Fig. 6D).
Increasing  salicylates concentration to 2 mM (Fig. 7)
gave  similar morphological features but with higher fre-
quencies. The ASA-treated sample at this concentration had
more  rounded cells and apoptotic bodies than at 0.4 mM
and  cells differed in their shapes from one another. For
example, numerous of these cells were ﬂattened, some
were  rounded and smooth and others rounded but retained
their  microvilli on their surface (Fig. 7A). A very distinctive
change in cell structure was seen in 2 mM ASCa treated
cells in which all of the cell population lost their pseu-
dopodial attachments, anchors and curled up (Fig. 7B). The
cells  also had smooth membrane surface, indicating the
loss  of microvilli and reduced signiﬁcantly in size which
increased the distance between them. This was an indi-
cation of the signiﬁcant level of apoptosis undergone by
those  cells which also reﬂected the role of ASCa as an anti-
proliferative agent at this concentration. Samples treated
with  2 mM SACa also showed the presence of apoptosis as
indicated  by the morphology of cells (Fig. 7C).
At higher concentrations (6 and 8 mM),  treated HT-1080
cells changed signiﬁcantly in their morphology com-
pared with the control (Fig. 5) and lower concentrations
(Figs. 6 and 7). Salicylates treated samples with these con-
centrations (6 mM)  large number of cells lost their anchors
and  microvilli and reduced signiﬁcantly in size (Fig. 8A–C).
Fig.  8A–C also shows the formation of apoptotic bodies. In
addition  to changes of HT-1080 cells towards apoptosis at
6  mM salicylates, Fig. 8D–F also shows blebbings emerg-
ing  from the cell surfaces which is considered as the main
feature for cells undergoing apoptotic cell death. Further-
more, HT-1080 cells also appeared round in shape, lacked of
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Fig. 7. The combined effect of salicylates and 200 M BrdU on the morphology of HT-1080 cells cultured for 48 h, (A) 2 mM ASA, (B) 2 mM ASCa, (C) 2 mM
SACa  (magniﬁcations A–C = 500×).
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nchors and decreased signiﬁcantly in size in comparison
o  the control and the corresponding treatments at lower
oncentrations.
.  Discussion
Salicylates have been extensively studied as chemopre-
entative and apoptotic-inducer drugs in cancer cells [21].
he  bioactivity of salicylates not only inhibit prostaglandin
ynthesis, but also target mitochondria and L-type Ca2+ sig-
alling  channels, a pathway that is upregulated in human
ancer  non-excitable cells. Salicylates modulate proinﬂam-
atory mediator release in mast cells via cyclooxygenase-ndependent mechanisms with the aid of Ca2+ signalling
22,23]. These studies indicated that ASA either enhances
at  ≤0.3 mM)  or inhibits (at >1 mM)  Ca2+ inﬂux [22]. In
ddition, our previous results have shown evidence of the HT-1080 cells cultured for 48 h, (A) 6 mM ASA, (B) 6 mM ASCa, (C) 6 mM
, B = 550×).
pro-apoptotic activity of SACa in HT-1080 cells at 0.4 mM
and  modulation of both pro- and anti-apoptotic proteins. At
0.4  mM SACa up-regulated the expression of p53, p21 and
Bax,  and down-regulated the anti-apoptotic protein, Bcl-2
[9].  These results are likely to indicate that ASCa induces
the  activation of the intrinsic apoptotic pathway, which
involves the activation of mitochondria. In addition, the
loss  of the transmembrane potential for inner membrane
in  mitochondria causes the release of pro-apoptotic pro-
teins  into the cytosol which subsequently activate caspases
to  mediate the destruction of the cell [24,25]. In addition,
this current study involves assessing the cytotoxicity of
ASA,  ASCa and SACa at higher concentrations (0–8 mM)
and  in the presence of BrdU in HT-1080 human ﬁbrosar-
coma cells. BrdU is a common reagent used to measure
cell proliferation, as it is readily incorporated in the de
novo  DNA synthesis during S-phase of cell cycle in place
scopy an
[
[
[
[
[
[
[
[
[
[
[
[
[
[26 E.J. Mahdi et al. / Journal of Micro
of thymidine of newly treated cells [26,27]. Therefore, it
was  interesting to see the combined effect of individual
salicylate and BrdU on mainly the ultrastructure of HT-
1080  by SEM.
The  combination of BrdU with different salicylates (ASA,
ASCa  and SACa) concentrations (0.4, 0.8, 2, 4, 6, 8 mM)
showed dual cytotoxic effects on metabolic activities of
HT-1080  cells. 0.4–2 mM salicylates showed mitogenic
effects particularly when HT-1080 cells were treated for
24  and 48 h, but not at 72 h. However, at higher con-
centrations (4–8 mM)  particularly after 48 h and 72 h, the
metabolic activities of HT-1080 cells decreased in time
and  concentration-dependent manners. These results may
indicate  that salicylates exert their anti-metabolic activi-
ties  after BrdU was consumed by HT-1080. Research has
shown  BrdU activated DNA damage signalling responses
and expressed wild-type p53, induces a DNA damage
response and reduced proliferation in A549 lung can-
cer  cells [28]. However, the presence of 6 mM salicylates
arrested the cell cycle at G0/G1 phase by approximately
17% compared to the control sample which is in agreement
with the previous results when only 0.4 mM SACa (no BrdU)
was  incorporated with HT-1080 cells at 0.4 and 0.8 mM [9].
These  results support the cytotoxic potential of salicylates
to  induce apoptosis, which was measured morphologically.
The treatment of HT-1080 cells with different concentra-
tions of ASA, ASCa and SACa in presence of BrdU showed
signiﬁcant ultrastructure changes, compared to the con-
trol  sample. It is interesting to observe the morphological
changes treated HT-1080 cells with BrdU. These treated
cells  curled up and exhibited a more round and swollen
shape. Similar changes were reported in BrdU-treated A549
lung  cancer cells after 7 days, there was an increased in the
size,  granularity and beta-galactosidase activity of these
cells.  In addition, BrdU upregulated the activation of Chk1,
Chk2  and p53 in lung cells [28].
The combined effect of salicylates and BrdU on the mor-
phology of HT-1080 cells caused cells to curl up and show
apoptotic features. The percentage of apoptosis signiﬁ-
cantly increased from 6% in lower salicylate concentration
to 100% as salicylate concentration increased to 8 mM.
SEM  of salicylate-treated HT-1080 cells at concentrations
above 4 mM showed distinguishable apoptotic morpho-
logical characteristics, including cell blebbings, presence
of  apoptotic bodies, roundness of cells and loss of pseu-
dopodial attachments and anchors. In addition, the cells
changed  shape becoming smaller and having a smoother
surface when compared to the control. These morphologi-
cal features give good evidence for the ability of salicylate
to  induce apoptosis.
5.  Conclusion
Results here demonstrate that ASA, ASCa and SACa pro-
vided  mainly morphological evidence of induced apoptosis
in  HT-1080 cells. The cytotoxicity of these salicylates and
the  induction of apoptotic cell death were in concentration-
dependent manner, which further contributes to the
development of these compounds to chemotherapy for
cancer.
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